Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trial

BACKGROUND: Anti-COVID-19 hyperimmune immunoglobulin (hIG) can provide standardized and controlled antibody content. Data from controlled clinical trials using hIG for the prevention or treatment of COVID-19 outpatients have not been reported. We assessed the safety and efficacy of subcutaneous anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Alemany, Andrea, Millat-Martinez, Pere, Corbacho-Monné, Marc, Suñer, Clara, Galvan-Casas, Cristina, Carrera, Caty, Ouchi, Dan, Prat, Núria, Ara, Jordi, Nadal, Nuria, Riel, Ricard, Funollet, Blanca, Ojeda-Ciurana, Carmen, Balague, Lluis Esteve, Salvador-González, Betlem, Arcarons, Anna Forcada, Vidal-Alaball, Josep, Del Cura-González, María Isabel, Barrientos, Ricardo Rodríguez, Ramos-Blanes, Rafel, Bou, Alberto Alum, Mondou, Elsa, Torres, Mireia, Campins, Neus, Sanz, Ana, Tang, Yonggiang, Rodriguez-Arias, Miquel Àngel, Bassat, Quique, Clotet, Bonaventura, Mitjà, Oriol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10005687/
https://www.ncbi.nlm.nih.gov/pubmed/36936402
http://dx.doi.org/10.1016/j.eclinm.2023.101898

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10005687/
https://www.ncbi.nlm.nih.gov/pubmed/36936402
http://dx.doi.org/10.1016/j.eclinm.2023.101898

Ejemplares similares